Medical technologies
-
Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
VARIPURE findings reported 100% acute procedural success with the VARIPULSE Pro Platform, 0.4% primary adverse event rate and a mean ablation time of 17.9 minutesi Omny-IRE data showed 82.5% of patients treated with the investigational OMNYPULSE Platform1remained free from documented atrial arrhythmia recurrence at 12 months under stringent monitoringii -
Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026
· Company to showcase MONARCH™ robotics platform and Polyphonic™ digital ecosystem · New ecosystem collaboration announced at the event will support the future of surgical intelligence -
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
· Next-generation intravascular lithotripsy (IVL) catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease1 · Faster pulsing reduces duration patients may experience procedure-induced ischemic time2 · Shockwave C2 Aero Fly builds on the best-in-class features of Shockwave C2 Aero, featuring leading deliverability, crossability and repositioning capabilities3 -
Johnson & Johnson Announces New Global Classification System for Surgical Outcomes
Peer-reviewed DISH Classification System establishes a standardized approach to reporting dehiscence, infection, seroma and hematoma across surgical specialties -
Johnson & Johnson Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence
Drawing on insights from leaders across healthcare, technology, policy and investment, the report introduces a common framework for surgical intelligence and outlines the foundations required to operationalize it responsibly at scale. -
Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy
Introducing MONARCH™ QUEST 3, the latest software update for the MONARCH™ Platform, designed to enhance planning, navigation, and targeting in the early detection of lung cancer1-3. -
-
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
· Dual Energy THERMOCOOL SMARTTOUCH SF Platform brings pulse field and radiofrequency energy together in a single catheter. · Integrated with the CARTO ecosystem, the platform gives physicians greater versatility to tailor treatment based on patient anatomy and case complexity.i -
Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS
Key oral presentations highlight new safety, efficacy and workflow improvements data to optimize irrigation and support consistent procedural outcomes.